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Cardiovascular diseases arising from atherosclerosis are the
leading causes of mortality and morbidity worldwide.
Lipid-lowering agents have been developed in order to treat
hypercholesterolemia, a major risk factor for atherosclerosis.
However, the prevalence of cardiovascular diseases is
increasing, indicating a need to identify novel therapeutic
targets and develop new treatment agents. Adenosine
receptors (ARs) are emerging as therapeutic targets in asthma,
rheumatoid arthritis, cancer, ischemia, and inflammatory
diseases. This study assessed whether LJ-1888, a selective
antagonist for A3 AR, can inhibit the development of
atherosclerosis in apolipoprotein E knock-out (ApoE−/−) mice
who are fed a western diet. Plaque formation was significantly
−/−
mice administered LJ-1888 than in mice not
lower in ApoE
administered LJ-1888, without any associated liver damage.
−/−
mice prevented western
LJ-1888 treatment of ApoE
diet-induced hypercholesterolemia by markedly reducing
low-density lipoprotein cholesterol levels and significantly
increasing high-density lipoprotein cholesterol concentrations.
−/−
mice administered
Reduced hypercholesterolemia in ApoE
LJ-1888 was associated with the enhanced expression of genes
involved in bile acid biosynthesis. These findings indicate that
LJ-1888, a selective antagonist for A3 AR, may be a novel
candidate for the treatment of atherosclerosis and hypercholesterolemia. [BMB Reports 2018; 51(10): 520-525]
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INTRODUCTION
Cardiovascular diseases including atherosclerosis are the
leading causes of death worldwide (1-3). Hypercholesterolemia
is considered a major risk factor for atherosclerosis, which has
resulted in the development of medications aimed at lowering
plasma cholesterol levels (4, 5). Because atherosclerosis is
characterized by increased plasma levels of low-density
lipoprotein cholesterol (LDL-chol) and reduced plasma
concentrations of high-density lipoprotein cholesterol
(HDL-chol) (6), agents that modify LDL-chol and HDL-chol
levels are needed to prevent and improve the outcomes of
atherosclerotic vascular diseases. Statins, which act as
3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase
inhibitors, are representative lipid-lowering medications that
have shown protective effects in cardiovascular diseases by
inhibiting cholesterol synthesis, enhancing the expression of
LDL receptors on the surface of hepatocytes, and increasing
anti-inflammatory responses (7). Other medications used to
lower LDL-chol levels include cholesterol absorption inhibitors,
bile acid sequestrants, and protein convertase subtilisin/kexin
type-9 (PCSK-9) inhibitors (8, 9). Moreover, elevated plasma
levels of HDL-chol have been closely associated with clinical
benefits in patients with cardiovascular diseases (10). For
example, cholesteryl ester transfer protein (CETP) inhibitors and
HDL mimetics have been shown to regulate HDL-chol levels,
suggesting that these agents may be therapeutically applicable
in the prevention and/or treatment of cardiovascular diseases
(10, 11). However, the worldwide morbidity and mortality rates
of cardiovascular diseases remain high (12), indicating a need to
identify new therapeutic targets and develop corresponding
medications.
Adenosine, an endogenous nucleoside, regulates various
physiological processes, including neurotransmission,
vasodilation, energy transfer, and signal transduction (13).
Extracellular adenosine levels are low under normal
physiological conditions, but increase in response to cellular
damage resulting from inflammation, ischemia, hypoxia, and
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trauma (14). Four adenosine receptor (AR) subtypes, A1, A2A,
A2B, and A3, mediate cellular signaling by adenosine and
modulate the biological effects of adenosine in organs (15).
Although the physiological roles of these four AR subtypes are
partially redundant, they are encoded by separate genes and
have unique functions (15). Therefore, selective agonists
and/or antagonists have been developed for each AR subtype
in order to treat various diseases (16). Investigations of A3 AR
agonists and/or antagonists have provided the identification of
pharmacological targets to treat myocardiac and cerebral
ischemia, cancer, asthma, glaucoma, and renal fibrosis (17,
18). LJ-1888 [(2R,3R,4S)-2-[2-chloro-6-(3-iodobenzylamino)-9Hpurine-9-yl]-tetrahydrothiophene-3,4-diol] is a novel, selective,
species-independent A3 AR antagonist (19) that has shown
protective effects in renal fibrosis induced by unilateral
ureteral obstruction (UUO) and transforming growth factor-1
(TGF-1) (20). However, its ability to protect against the
development of atherosclerosis has not yet been determined.
This study therefore investigated the effects of LJ-1888 on the
development of atherosclerosis in apolipoprotein E knock-out
−/−
(ApoE ) mice who were fed a western diet (WD).
Atherosclerotic plaque formation was significantly lower in
−/−
mice than in untreated ApoE−/−
LJ-1888-treated ApoE
mice. Moreover, LJ-1888 supplementation suppressed
−/−
mice through
WD-induced hypercholesterolemia in ApoE

lowering LDL-chol and raising HDL-chol levels. These effects
of LJ-1888 were mechanistically associated with alterations in
the expression of genes catalyzing bile acid biosynthesis.
Taken together, these results suggest that LJ-1888 may be
useful in the prevention and/or treatment of atherosclerosis
and hypercholesterolemia.

RESULTS
LJ-1888 ameliorates the formation of atherosclerotic plaques
in apolipoprotein E knock-out mice

To explore the effects of the selective A3 AR antagonist LJ-1888
−/−
on the development of atherosclerosis, six-week-old ApoE
mice were fed normal chow (ND) or a western diet (WD), with
or without two dosages of LJ-1888 (0.025% and 0.05%), for 12
weeks. Body weight (BW) gains were higher in WD fed than in
−/−
mice, but there were no differences among
ND fed ApoE
WD fed groups in BW gain (Supplementary Fig. 1A) or food
intake (Supplementary Fig. 1B). After 12 weeks, the mice were
sacrificed. The ratios of liver weight to BW were similar in all
groups (Supplementary Fig. 1C), but the ratios of epididymal
fat to BW were significantly higher in WD-fed than in ND-fed
mice, with LJ-1888 supplementation having no effect on the
ratio of epididymal fat to BW (Supplementary Fig. 1D).
Isolated whole aortas of these mice, from the ascending to
the femoral region, were dissected longitudinally and stained
with Oil red O to analyze atherosclerotic plaque formation.
Plaque formation was significantly greater in WD fed (3.79%)
−/−
mice. However, supplementhan in ND fed (1.58%) ApoE
tation with 0.025% (2.02%) and 0.05% (2.30%) LJ-1888
significantly inhibited WD-induced atherosclerotic plaque
formation on the aortas of WD fed mice (Fig. 1A and B). To
further validate the effects of LJ-1888 on atherosclerotic plaque
formation, the aortic sinuses of hearts from the four groups of
mice were dissected. As expected, atherosclerotic plaque
formation on aortic sinuses was lowest in the ND fed group
and highest in the WD fed group. Consistent with the plaque
formation on the aortas, the plaque formation on the aortic
sinuses was markedly lower in WD fed mice receiving
0.025% and 0.05% LJ-1888 than in mice fed WD alone (Fig.
1C and D). These results suggested that the selective A3 AR
antagonist LJ-1888 has anti-atherosclerotic effects in ApoE−/−
mice fed WD.

LJ-1888 ameliorates hypercholesterolemia in western diet fed
apolipoprotein E knock-out mice
Fig. 1. LJ-1888 ameliorates the formation of atherosclerotic plaque
in apolipoprotein E knock-out mice. (A) Quantification of Oil red
O-stained areas on whole aortas from indicated groups (n =
5-12). (B) Representative en face images of whole aortas from
indicated groups. (C) Quantification of plaque areas on aortic
sinuses of indicated groups (n = 5-12). (D) Representative images
of Oil red O-stained areas of frozen sections of aortic sinuses
from indicated groups. Data are shown as mean ± SEM. *P ＜
0.05, **P ＜ 0.01 versus ND group; #P ＜ 0.05, ##P ＜ 0.01
versus WD group.
http://bmbreports.org

Hypercholesterolemia is a major risk factor for the development
of cardiovascular diseases including atherosclerosis (1). Elevated
levels of LDL-chol in the circulation increase endothelial
permeability, leading to the accumulation of lipids in the arterial
walls and subsequently triggering atherosclerosis (3). In contrast
to LDL-chol, HDL-chol contributes to the prevention of
atherosclerosis development by enhancing reverse cholesterol
transport (21). Therefore, we tested whether LJ-1888-mediated
BMB Reports
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anti-atherogenic effects are associated with reduced hypercholesterolemia in ApoE−/− mice. Total cholesterol levels were
found to be about two-fold higher in WD fed (1218 ± 40 mg/dl)
−/−
mice. Supplementhan in ND fed (679 ± 41 mg/dl) ApoE
tation with 0.025% (719 ± 53 mg/dl) and 0.05% (964 ± 74
mg/dl) LJ-1888 significantly reduced WD-mediated hypercholesterolemia compared to the WD group (Fig. 2A). Plasma
LDL-chol levels showed a similar trend as total cholesterol, with
WD fed mice having the highest level (279 ± 13 mg/dl), ND
fed mice having the lowest level (97 ± 6 mg/dl), and mice fed
WD plus 0.025% (151 ± 14 mg/dl) and 0.05% (216 ± 20
mg/dl) LJ-1888 having significantly lower plasma LDL-chol
−/−
mice fed WD alone (Fig. 2B).
concentrations than ApoE
Supplementation with LJ-1888 also prevented the WD-mediated
reduction in HDL-chol levels in ApoE−/− mice. HDL-chol levels
were lower in WD fed (18 ± 1.2 mg/dl) than in ND fed (23 ±
3.5 mg/dl) mice, whereas mice fed WD plus 0.025% (30 ± 1.9
mg/dl) and 0.05% (30 ± 3.2 mg/dl) LJ-1888 had significantly
higher HDL-chol concentrations than mice fed WD alone (Fig.
2C). In contrast, although plasma triglyceride (TG) levels were
−/−
mice, LJ-1888
lower in WD fed than in ND fed ApoE
supplementation had no effect on plasma TG levels (Fig. 2D),
and glucose levels were slightly, but not significantly, higher in
WD fed than in ND fed mice (Fig. 2E).
To test the liver toxicity of LJ-1888, we measured the serum
concentrations of alanine aminotransferase (ALT), aspartate
−/−
mice.
aminotransferase (AST), and albumin (ALB) in ApoE

Controlling lipoprotein and cholesterol levels is important for
reducing the risk of atherosclerosis (1, 21, 22). Hypercholesterolemia may be ameliorated by lowering LDL-chol and TG
concentrations and by increasing HDL-chol concentrations,
using agents such as HMG-CoA reductase inhibitors,
cholesterol absorption inhibitors, bile acid sequestrants, and
proprotein convertase subtilisin/kexin type-9 (PCSK-9)
inhibitors (7-9, 23, 24). We therefore assessed the mechanism
by which LJ-1888 improves hypercholesterolemia in WD fed
−/−
mice. First, we measured the expression levels of
ApoE
cholesterol transport genes, including LDL receptor (Ldlr) and
the ATP-binding cassette sub-family G member 5/8 (Abcg5/8),
in the livers of the four groups of mice. Ldlr gene expression
was significantly lower in the WD and WD+LJ0.025 groups
than in the ND group, but this was not the case in the
WD+LJ0.05 group, suggesting that Ldlr gene expression was
not associated with the anti-atherogenic effects of LJ-1888 (Fig.
3A). In addition, Abcg5/8 mRNA levels did not differ among
the four groups (Fig. 3A), indicating that LJ-1888 does not
−/−
mice by altering
ameliorate hypercholesterolemia in ApoE

Fig. 2. LJ-1888 ameliorates hypercholesterolemia in western diet
fed apolipoprotein E knock-out mice. Plasma concentrations of (A)
total cholesterol (T-chol), (B) low density lipoprotein cholesterol
(LDL-chol), (C) high density lipoprotein cholesterol (HDL-chol), (D)
triglycerides (TG), (E) glucose, (F) ALT, (G) AST, and (H) ALB of
indicated groups (n = 5-12). Data are shown as mean ± SEM.
*P ＜ 0.05, **P ＜ 0.01 versus ND group; #P ＜ 0.05, ##P ＜
0.01 versus WD group.

Fig. 3. LJ-1888 enhances the expression of bile acid synthesis
related genes in the liver. Levels of expression of (A) cholesterol
transport related genes and (B) bile acid biosynthesis genes in the
livers of indicated groups (n = 4). Data are shown as mean ±
SEM. *P ＜ 0.05, **P ＜ 0.01 versus ND group; #P ＜ 0.05, ##P ＜
0.01 versus WD group.
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We found that ALT and AST levels, but not ALB levels, were
−/−
mice (Fig. 2F-G),
higher in WD fed than in ND fed ApoE
with LJ-1888 supplementation slightly ameliorating WD-induced
liver damage.

LJ-1888 enhances the expression of bile acid biosynthesis
genes in the livers of apolipoprotein E knock-out mice

http://bmbreports.org
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the expression of cholesterol transport genes.
Next, we tested the effects of LJ-1888 on the expression of
genes involved in bile acid biosynthesis (25). The classical
pathway of bile acid synthesis is initiated by cholesterol
7-hydroxylase (Cyp7a1), with bile acid intermediates further
hydroxylated by sterol 12-hydroxylase (Cyp8b1). In contrast,
the major enzymes in the alternative pathway of bile acid
synthesis include sterol 27-hydroxylase (Cyp27a1) and
25-hydroxycholesterol 7-hydroxylase (Cyp7b1) (26). LJ-1888
supplementation induced the expression of bile acid
biosynthetic genes. Cyp7al mRNA levels were significantly
higher in both the WD+LJ0.025 and WD+LJ0.05 groups than
in the ND group, but this was not the case in the WD group.
Moreover, Cyp7a1 mRNA levels were markedly higher in the
WD+LJ0.05 group than in the WD group. Cyp8b1, Cyp27a1,
and Cyp7b1 mRNA levels were lower in the WD group than
in the ND group, but were similar in the ND, WD+LJ0.025,
and WD+LJ0.05 groups (Fig. 3B).
To analyze the mechanism by which LJ-1888 induces the
expression of these genes, including those encoding bile acid
biosynthesis proteins, we analyzed the mRNA levels of the
transcription factors involved in regulating enzymes for bile
acid biosynthesis. Liver X receptors (LXRs) are a family of
pivotal transcription factors involved in regulating lipid and
cholesterol metabolism. LXR and LXR form heterodimers
with the retinoic acid receptor (RXR), leading to transcription
of various genes such as Cyp7a1 and sterol regulatory element

Fig. 4. Effects of LJ-1888 on the expression of transcription factors
for bile acid synthesis. Levels of expression of mRNAs encoding
transcription factors regulating the synthesis of (A) bile acids and
(B) lipids in the livers of indicated groups (n = 4). Data are
shown as mean ± SEM. *P ＜ 0.05, **P ＜ 0.01 versus ND
#
##
group; P ＜ 0.05, P ＜ 0.01 versus WD group.
http://bmbreports.org

binding factor 1c (Srebf1c) (26). We found that LXR (Nr1h3)
mRNA levels were significantly higher in the WD+LJ0.025
group than in the WD group (Fig. 4A) and tended to be higher
in the WD+LJ0.05 group than in the WD group. In contrast,
the levels of LXR (Nr1h2) and Rxra mRNAs did not differ
among the four groups.
Farnesoid X receptor (Fxr) suppresses Cyp7a1 transcription
by controlling the expression of small heterodimer partner
(Shp) (27). Paradoxically, Fxr mRNA levels were higher in the
WD+LJ0.025 and WD+LJ0.05 groups than in the WD group.
In addition, LJ-1888 supplementation altered the expression of
genes encoding peroxisome proliferator-activated receptors
(Ppars) and Srebf1c (Fig. 4B). These findings indicate that
−/−
mice by
LJ-1888 may inhibit hypercholesterolemia in ApoE
altering the expression of genes involved in bile acid
biosynthesis.

DISCUSSION
Hypercholesterolemia, or high levels of cholesterol in the
blood, enhances the risks of cardiovascular diseases, such as
heart attack and stroke, induced by atherosclerosis (5, 6). High
levels of circulating cholesterol generate sticky deposits on the
walls of arteries, narrowing or blocking blood flow to organs
and resulting in heart attack or stroke (22). Lifestyle
modifications and various medications can lower blood
cholesterol (6, 28). Statins are a class of HMG-CoA reductase
inhibitors commonly used to reduce high cholesterol level that
are effective in most individuals, reducing total cholesterol
concentrations by about 50% on average (29). However,
statins cannot be used in certain people, including pregnant
women and patients with liver disease, and they also have side
effects such as myositis, joint pain, stomach upset, and liver
damage (30). Other drugs used to treat high LDL-chol, low
HDL-chol, and high TG, alone or in combination with statins,
include niacin, bile acid sequestrants, cholesterol absorption
inhibitors, and fibric acid derivatives, but these agents also
have side effects as well as low efficacy (31, 32). Therefore, it
is necessary to identify novel targets and develop drugs in
order to treat hypercholesterolemia and atherosclerosis.
Previous studies have shown that adenosine/AR signaling
participates in the modulation of lipid availability, including
lipolysis and cholesterol efflux (33, 34). Adenosine/A1 AR
signaling has been shown to suppress lipolysis on adipocytes
through the cyclic adenosine monophosphate (cAMP)-mediated
inhibition of lipase activity (35, 36). Activation of A2A AR has
also been shown to augment ATP-binding cassette transporter
ABCA1 and sterol 27-hydroxylase (CYP27A1) expression,
leading to enhancing cholesterol efflux from macrophages
(37). However, the role of adenosine/A3 AR signaling in
hyperlipidemia and atherosclerosis is unclear. Jones et al. has
shown that A3 AR deficiency does not affect the formation of
atherosclerotic plaque in ApoE−/− mice fed high-fat diet (30%
fat) for five months, however, the levels of plasma cholesterol
BMB Reports
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and lipids were not determined in these mice (38). The
differences in experimental design would affect any
comparison of the results between the findings of Jones et al.
and the present findings. In addition, LJ-1888 may have
poly-pharmacological effects, even though LJ-1888 was
developed as a selective A3 AR antagonist. Recently, Yu et al.
presented the poly-pharmacological effects of A3 AR agonist
(IB-MECA), which have shown the agonistic role of PPAR and
antagonistic role of PPAR (39). Therefore, further study is
needed to examine whether the role of LJ-1888 as a selective
antagonist for A3 AR is responsible for its anti-atherogenic
effects or not.
Atherosclerosis is a chronic inflammatory disease induced by
high levels of lipids and reactive oxygen species (3). This
condition may be inhibited by targeting molecules involved in
inflammatory responses and hypercholesterolemia (40, 41).
LJ-1888 treatment was shown to block UUO- and
TGF-1-induced activation of c-Jun N-terminal kinase and
extracellular signal- regulated kinase involved in inflammatory
responses (20). While we have not explored the role of LJ-1888
in inflammation, the possibility that LJ-1888 shows
anti-inflammatory properties in atherosclerosis remains. This
−/−
mice
study showed that LJ-1888 protected WD-fed ApoE
against the development of atherosclerosis by ameliorating
hypercholesterolemia. Administration of LJ-1888 induced the
expression of genes involved in bile acid biosynthesis, which
may be related to the amelioration of hypercholesterolemia.
Taken together, these findings show that LJ-1888, a selective
antagonist for A3 AR, might be a novel candidate for preventing
and/or treating atherosclerosis and hypercholesterolemia.

MATERIALS AND METHODS
Animal experiments

All animal studies were approved by the Institutional Animal
Care and Usage Committee of Ewha Womans University
−/−
(B6.KOR/Stm-Apoe) mice
(IACUC 2001-01-008). ApoE
were purchased from Central Laboratory Animal Inc and
housed under a 12-hour day-night cycle with free access to
water and food in a specific pathogen-free system.
−/−
mice were randomly divided into four
Six-week-old ApoE
groups. The ND group consisted of five mice fed a normal
chow diet supplemented with vehicle; the WD group
consisted of 12 mice fed a western diet, consisting of 20% fat
and 0.15% cholesterol (D09072603) and purchased from
Research Diets Inc (USA), supplemented with vehicle; and the
WD+LJ0.025 and WD+LJ0.05 groups consisted of 12 mice
each fed a western diet supplemented with 0.025% and
0.05% LJ-1888, respectively.

Statistical analysis

All data shown in figures are presented as mean ± SEM.
Statistical significance was determined by Student’s t-tests (for
in vitro experiments) and Mann-Whitney U tests (for in vivo
524 BMB Reports

experiments).
Detailed materials and methods are available in the
supplementary file.
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